Worldwide Condensyl™ and Procrelia™ are the first and currently only nutritional support brands that are statistically superior to no treatment in improving pregnancy rates in couples resistant to practices of Assisted Reproductive Technologies (ART) in which there was a component of male infertility.
In published clinical studies the most difficult cases were considered, i.e. men with high level of sperm DNA fragmentation or decondensation of the sperm nucleus, both predictive of impaired fertility, and being part of couples with a history of at least two ART failures. Treatment with Condensyl ™ significantly reduced both indices and pregnancy was obtained from patients who reported such improvements. The number and the percentage of pregnancies obtained were statistically superior to those obtained in the untreated controls and such as to be perhaps better than pregnancy rates expected in couples not carrying the serious risk factors included in the studies.
55% of pregnancies with term delivery occurred spontaneously, i.e. before the couple had time to undergo the planned new ART cycle (Dattilo et a. 2014).
This is a kinf of revolution that brought Condensyl™ to the attention of the international scientific community. These data are now waiting to be confirmed by several studies that are already ongoing.
Clinical studies carried out so far mainly investigated male infertility because it is the model in which it is easier to see and measure any effects. Given the similarity of the issue, we expect a similar effectiveness on pregnancy rates also in female infertility. The results already achieved with Procrelia ™ (Cornet et al. 2015) confirm these expectations.
Among couples with a female problem/treatment as many as 67% of pregnancies occurred spontaneously (Cornet et al 2015)
Studies on the use of Condensyl to evaluate the effect of supplementation in women with polycystic ovaries or endometriosis, with or without fertility problems, are now under way.